ImmuneRegen Signs MTA Agreement With Archimedes Development

ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, has announced the execution of a material transfer agreement or MTA with a UK-based specialty pharmaceutical company Archimedes Development, an initial step to enable the companies to investigate possible synergies between their technology platforms.

Hal Siegel, chief scientific officer of ImmuneRegen, said: "Multiple studies in different model systems have shown that Homspera can protect experimental animals and enhance their immune responses to vaccine-delivered antigens, DNA-encoded viral proteins or tumor antigens, as well as provide protection in our anthrax and influenza therapeutic studies.

In addition to these findings in animals where Homspera has been administered intranasally as a liquid, inhaled or injected under the skin, we have shown in laboratory studies that Homspera can stimulate blood-forming stem cells to produce more white blood cell precursors, particularly those for granulocytes and macrophages, mature blood cells which play a significant role in immune responses. The ability to administer Homspera intranasally is one we are particularly interested in pursuing."